Klaus Junge

1.4k total citations · 1 hit paper
18 papers, 1.1k citations indexed

About

Klaus Junge is a scholar working on Surgery, Public Health, Environmental and Occupational Health and Genetics. According to data from OpenAlex, Klaus Junge has authored 18 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Surgery, 6 papers in Public Health, Environmental and Occupational Health and 4 papers in Genetics. Recurrent topics in Klaus Junge's work include Research on Leishmaniasis Studies (5 papers), Glioma Diagnosis and Treatment (4 papers) and Reconstructive Surgery and Microvascular Techniques (3 papers). Klaus Junge is often cited by papers focused on Research on Leishmaniasis Studies (5 papers), Glioma Diagnosis and Treatment (4 papers) and Reconstructive Surgery and Microvascular Techniques (3 papers). Klaus Junge collaborates with scholars based in United States, Germany and United Kingdom. Klaus Junge's co-authors include H. Sindermann, T. K. Jha, Shyam Sundar, Jonathan Berman, C.P. Thakur, Juergen Engel, A.D.M. Bryceson, Christina Fischer, Alessia M. Lardi and Jian Farhadi and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Clinical Infectious Diseases.

In The Last Decade

Klaus Junge

16 papers receiving 1.0k citations

Hit Papers

Oral Miltefosine for Indian Visceral Leishmaniasis 2002 2026 2010 2018 2002 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Oral Miltefosine for Indian Visceral Leishmaniasis
    2002 568 citations Shyam Sundar, T. K. Jha et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Klaus Junge United States 11 677 377 142 134 111 18 1.1k
Estelle Seillès France 16 47 0.1× 293 0.8× 31 0.2× 37 0.3× 215 1.9× 51 1.0k
Mònica Arman United Kingdom 12 508 0.8× 86 0.2× 58 0.4× 9 0.1× 110 1.0× 18 837
Kodjo Ayi Canada 19 524 0.8× 278 0.7× 67 0.5× 17 0.1× 270 2.4× 23 1.4k
Kazuoki Osumi Japan 16 136 0.2× 311 0.8× 15 0.1× 36 0.3× 224 2.0× 22 890
Semíramis Jamil Hadad do Monte Brazil 17 164 0.2× 182 0.5× 44 0.3× 16 0.1× 136 1.2× 57 886
Hugo Sousa Portugal 28 126 0.2× 529 1.4× 21 0.1× 7 0.1× 527 4.7× 83 1.8k
Milton J. Friedman United States 13 576 0.9× 57 0.2× 95 0.7× 10 0.1× 130 1.2× 17 948
ArthurJ. Ammann United States 7 89 0.1× 639 1.7× 28 0.2× 22 0.2× 618 5.6× 8 1.2k
Papa Alioune Ndour France 15 446 0.7× 58 0.2× 99 0.7× 3 0.0× 82 0.7× 28 908
Susanne Marschner United States 22 122 0.2× 119 0.3× 20 0.1× 7 0.1× 128 1.2× 55 1.3k

Countries citing papers authored by Klaus Junge

Since Specialization
Citations

This map shows the geographic impact of Klaus Junge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaus Junge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaus Junge more than expected).

Fields of papers citing papers by Klaus Junge

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaus Junge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaus Junge. The network helps show where Klaus Junge may publish in the future.

Co-authorship network of co-authors of Klaus Junge

This figure shows the co-authorship network connecting the top 25 collaborators of Klaus Junge. A scholar is included among the top collaborators of Klaus Junge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klaus Junge. Klaus Junge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
Wick, Wolfgang, et al.. (2019). Longitudinal analysis of quality of life following treatment with asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients.. Journal of Clinical Oncology. 37(15_suppl). 2022–2022. 1 indexed citations
3.
Lardi, Alessia M., et al.. (2018). The use of tranexamic acid in microsurgery—is it safe?. Gland Surgery. 7(S1). S59–S63. 35 indexed citations
4.
Lardi, Alessia M., Mark Ho-Asjoe, Klaus Junge, & Jian Farhadi. (2017). Capsular contracture in implant based breast reconstruction—the effect of porcine acellular dermal matrix. Gland Surgery. 6(1). 49–56. 36 indexed citations
5.
Wick, Wolfgang, Harald Fricke, Klaus Junge, et al.. (2014). A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma. Clinical Cancer Research. 20(24). 6304–6313. 95 indexed citations
6.
7.
Platten, Michael, Harald Fricke, Klaus Junge, et al.. (2014). Final results of APG101_CD_002: APG101 plus reirradiation versus reirradiation in the treatment of patients with progressive glioblastoma.. Journal of Clinical Oncology. 32(15_suppl). 2006–2006. 2 indexed citations
8.
Schürer, Michael, Katharina Erb, Klaus Junge, et al.. (2011). Drug Interaction of Spirapril Hydrochloride Monohydrate and Hydrochlorothiazide. Arzneimittelforschung. 53(6). 414–419.
9.
Hervig, Tor, José Luis Bueno, Emma Castro, et al.. (2008). A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion. 48(6). 1061–1071. 79 indexed citations
10.
Johansson, Pär I., Maureen G. Conlan, Michèle Jacquet, et al.. (2006). Transfusion of 7‐day‐old amotosalen photochemically treated buffy‐coat platelets to patients with thrombocytopenia: a pilot study. Transfusion. 46(3). 424–433. 32 indexed citations
11.
Bhattacharya, Sujit, T. K. Jha, Shyam Sundar, et al.. (2004). Efficacy and Tolerability of Miltefosine for Childhood Visceral Leishmaniasis in India. Clinical Infectious Diseases. 38(2). 217–221. 110 indexed citations
12.
Sundar, Shyam, T. K. Jha, H. Sindermann, et al.. (2003). Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. The Pediatric Infectious Disease Journal. 22(5). 434–438. 70 indexed citations
13.
Sundar, Shyam, et al.. (2003). . The Pediatric Infectious Disease Journal. 22(5). 434–438. 7 indexed citations
14.
Mace, Joseph R., Mary Lou Keohan, Klaus Junge, et al.. (2003). Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.. PubMed. 9(16 Pt 1). 5829–34. 14 indexed citations
15.
Sundar, Shyam, T. K. Jha, C.P. Thakur, et al.. (2002). Oral Miltefosine for Indian Visceral Leishmaniasis. New England Journal of Medicine. 347(22). 1739–1746. 568 indexed citations breakdown →
16.
Engel, J., R. Felberbaum, Klaus Junge, Thomas Reissmann, & Klaus Diedrich. (2002). Inhibin B on the day of HCG-administration is a predictive factor for failure in assisted reproduction cycles. Archives of Gynecology and Obstetrics. 268(4). 278–280. 2 indexed citations
17.
Sundar, Shyam, T. K. Jha, C.P. Thakur, et al.. (2002). Oral Miltefosine for Indian visceral leishmaniasis. N Engl J Med. 3 indexed citations
18.
Erb, Katharina, et al.. (2002). Novel Formulations of Cetrorelix Acetate in Healthy Men: Pharmacodynamic Effects and Noncompartmental Pharmacokinetics. The Journal of Clinical Pharmacology. 42(9). 995–1001. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Estelle Seillès Breakdown of academic impact, for papers by Mònica Arman Breakdown of academic impact, for papers by Kodjo Ayi Breakdown of academic impact, for papers by Kazuoki Osumi Breakdown of academic impact, for papers by Semíramis Jamil Hadad do Monte Breakdown of academic impact, for papers by Hugo Sousa Breakdown of academic impact, for papers by Milton J. Friedman Breakdown of academic impact, for papers by ArthurJ. Ammann Breakdown of academic impact, for papers by Papa Alioune Ndour Breakdown of academic impact, for papers by Susanne Marschner
Rankless by CCL
2026